Hybrid Email and Outpatient Clinics to Optimize Maintenance Therapy in Acute Lymphoblastic Leukemia.
Tushar MungleAnanya MahadevanParag DasAmit K MehtaManash P GogoiBishwaranjan JanaNiharendu GharaDebjani GhoshVaskar SahaShekhar KrishnanPublished in: Journal of pediatric hematology/oncology (2023)
Acute lymphoblastic leukemia treatment includes an outpatient (OP)-based 2-year maintenance therapy (MT). Over an 8-year period, patients were transited from only OP to a hybrid e-clinic/OP-clinic model. Electronic and patient-held medical records of acute lymphoblastic leukemia patients aged 1 to 18 years during MT were used to analyze demographics, drug doses, treatment response and cost. A survey evaluated family satisfaction with the hybrid service. Four hundred and seventy-eight children, all with at least 1 year of MT from March 13, 2014 to March 24, 2022 were grouped into 4 treatment eras, representing the transition from all OP (era 1) to the current hybrid MT practice (era 4). Cohort demographics were similar across all eras. With transition to era 4, OP visits decreased to a third (16 to 18/48 visits). Practice optimization in era 2 resulted in higher MT dose intensity in subsequent eras (era 1: median 82% [interquartile range, 63 to 97]; era 2: 93% [73 to 108]; era 3: 88% [68 to 106]; era 4: 90% [74 to 114], P<0·0001), with no differences in absolute neutrophil count or neutropenia-related toxicity (P=0.8). The hybrid service reduced MT expenses by ~50% and families (133/156, 85%) reported being very satisfied. Our experience indicates that a hybrid model is feasible, effective and less burdensome for patients and families.
Keyphrases
- acute lymphoblastic leukemia
- end stage renal disease
- healthcare
- ejection fraction
- newly diagnosed
- chronic kidney disease
- peritoneal dialysis
- mental health
- young adults
- emergency department
- patient reported outcomes
- acute myeloid leukemia
- mesenchymal stem cells
- quality improvement
- bone marrow
- drug induced
- oxide nanoparticles